Leuprolide in Treating Adults With Hypogonadotropism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004438|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : March 25, 2015
RATIONALE: Hypogonadotropism is an abnormal condition caused by decreased production of gonadotropins, a group of hormones that stimulate the parts of the reproductive system that produce and release eggs from the ovaries or sperm from the testicles. Leuprolide may stimulate the production of gonadotropins and be effective in increasing testosterone in men and inducing ovulation in women.
PURPOSE: Clinical trial to study the effectiveness of leuprolide in treating adults who have hypogonadotropism.
|Condition or disease||Intervention/treatment||Phase|
|Hypogonadism||Drug: leuprolide||Not Applicable|
PROTOCOL OUTLINE: Male patients receive leuprolide subcutaneously every 5 days for up to one year and are followed at weeks 4, 6, 8, and 12, then every 2 months.
Female patients receive leuprolide subcutaneously on days 1, 6, and possibly 11. Patients are followed 2 months after the last injection.
Completion date provided represents the completion date of the grant per OOPD records
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||45 participants|
|Official Title:||Study of Leuprolide in Adults With Hypogonadotropism|
|Study Start Date :||September 1997|
|Study Completion Date :||September 2002|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004438
|United States, Illinois|
|University of Chicago Children's Hospital|
|Chicago, Illinois, United States, 60637|
|Study Chair:||Robert L. Rosenfield||University of Chicago|